Research Funding

DOD Duchenne Muscular Dystrophy Research Program Funding Opportunities for Fiscal Year 2019

The FY19 Defense Appropriation provides $3.2 million (M) to the Department of Defense Duchenne Muscular Dystrophy Research Program (DMDRP) to support innovative, high-impact Duchenne muscular dystrophy research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 DMDRP Program Announcement and General Application Instructions for the following award mechanism is posted on the Grants.gov.

IMPORTANT:  All applications for the FY19 DMDRP Idea Development Award must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology of DMD. Eligible therapeutic strategies include: gene therapy, genome editing, oligonucleotide therapies, exon skipping, protein therapeutics, and cell therapies.

Studies proposed under this award may include:

  • Delivery to skeletal muscle and heart (ligand assisted, nanoparticles, identification of biological barriers to delivery, alternative vectors)
  • Immunosuppression, and other strategies to deal with neutralizing antibodies
  • Re-dosing
  • Targeting muscle stem cells
  • Cell based therapies, including but not limited to: selection of novel cell types, expansion, root of delivery, differentiation, and integration

Studies proposed under this award should not include:

  • Therapies addressing secondary pathology of DMD (fibrosis, inflammation, muscle atrophy, oxidative stress, mitochondrial defects, abnormal peripheral circulation)
  • Small molecules
  • Efficacy testing absence of mechanistic understanding,
  • Evaluation of standard vectors or delivery technologies

https://cdmrp.army.mil/funding/dmdrp

Idea Development Award

Principal Independent investigator (PI): Independent investigators at all academic levels (or equivalent) are eligible to be names as a PI.

  • Supports the development of innovative, high-risk/high-reward research that could lead to critical discoveries or major advancements that will accelerate progress in improving outcomes for individuals with DMDM.
  • Applications must address opportunities and challenges in the development of safe and effective macromolecular and cellular therapies that address primary pathology or DMD.
  • Preliminary data are required.
  • Clinical trials are not allowed.
  • Maximum funding of $350,000 in direct costs (plus indirect costs)
  • Period of performance not to exceed years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the DMDRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

DOD Vision Research Program Funding Opportunities for Fiscal Year 2019

The FY19 Defense Appropriation provides $20 million (M) to the Department of Defense Vision Research Program (VRP) to support impactful military-relevant vision research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 VRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

Applications submitted to the FY19 VRP must address at least one of the following Focus Areas:

  • Eye injury or visual dysfunction as related to a military-relevant traumatic event.  Examples of military-relevant trauma may include, but are not limited to:
  • Blast, blunt, thermal, or chemical trauma
  • Trauma caused by directed energy weapons such as laser, microwaves, and particle beams
  • Diagnosis and treatment of eye injuries in austere environments and prolonged field care settings

https://cdmrp.army.mil/funding/vrp

Focused Translational Team Science Award (FTTSA) – Preproposal due August 6, 2019

  • The overall Principal Investigator (PI) must be an independent investigator at or above the level of Associate Professor (or equivalent) with demonstrated success in leading large collaborative research project(s).
  • Leaders of individual projects may be independent investigators at all academic levels (or equivalent).
  • The overall lead PI is required to devote a minimum of 20% effort to this award.

Preproposal is required; application submission is by invitation only.

  • Supports a highly collaborative and translational team initiative that will fundamentally advance the understanding and treatment of eye injury and/or visual dysfunction that result from a military-relevant trauma.
  • Must address one or more of the FY19 VRP Focus Areas.
  • Applications shall include at least three but no more than five distinct research projects that together form a concerted and synergistic effort to address an overarching challenge.
  • Preliminary data required for each individual project.
  • One of the projects may include a pilot clinical trial where limited clinical testing of a novel intervention is conducted to inform the feasibility, rationale, and design of subsequent clinical trials.
  • Must have a detailed Implementation Plan for participating research groups to coordinate efforts, facilitate collaboration, and create synergy.
  • Maximum funding of $5,000,000 for direct costs (plus indirect costs)
  • The maximum period of performance is years

Investigator-Initiated Research Award (IIRA) – Preproposal due August 6, 2019

Independent investigators at all academic levels (or equivalent).

Preproposal is required; application submission is by invitation only.

  • Supports studies that will yield highly impactful discoveries or major advancements in research and/or patient care of eye injury and/or visual dysfunction as related to military-relevant trauma.
  • Must address one or more of the FY19 VRP Focus Areas.
  • Funding Level 1 supports exploratory, high-risk/high-reward research in the earliest stages of development. No preliminary data is required.
  • Funding Level 2 supports the advancement of more mature research toward clinical translation.  Preliminary data required.
  • It is the responsibility of the applicant to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the stage and maturity of the research, rather than the amount of the budget.
  • Clinical trials are not allowed

Funding Level 1:

  • Maximum funding of $260,000 for direct costs (plus indirect costs)
  • The maximum period of performance is years

Funding Level 2:

  • Maximum funding of $500,000 for direct costs (plus indirect costs)
  • The maximum period of performance is years

Translational Research Award (TRA) – Preproposal due August 6, 2019

Independent investigators at all academic levels (or equivalent).

Preproposal is required; application submission is by invitation only.

  • Supports translational research that moves promising laboratory research into clinical applications.
  • It is expected that an Investigational New Drug (IND)/Investigational Device Exemption (IDE) application will be submitted during or by the end of the period of performance.
  • Must address one or more of the FY19 VRP Focus Areas.
  • Preliminary data required.
  • May include a pilot clinical trial component where limited clinical limited clinical testing of a novel intervention is conducted to inform the feasibility, rationale, and design of subsequent clinical trials.
  • Maximum funding of $750,000 for direct costs (plus indirect costs)
  • The maximum period of performance is years

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://ebrap.org/.  For more information about the VRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

DOD Kidney Cancer Research Program Funding Opportunities for Fiscal Year 2019

The FY19 Defense Appropriation provides $20 million (M) to the Department of Defense Kidney Cancer Research Program (KCRP) to support research of exceptional scientific merit in the area of kidney cancer.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

FY19 KCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

https://cdmrp.army.mil/funding/kcrp

Academy of Kidney Cancer Investigators – Dean Award – Letter of Intent due September 17, 2019

Dean must be an established kidney cancer researcher.

  • Supports visionary individuals who are established kidney cancer researchers with a strong record of mentoring and commitment to leadership.
  • Academy Dean will oversee an interactive virtual academy of Early-Career Investigators and their designated mentors, facilitate regular interactive communication among all Academy members, and assess the research progress and career progression of the Early-Career Investigators.
  • Maximum funding of $625,000 for direct costs (plus indirect costs).
  • Maximum period of performance 5
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Academy of Kidney Cancer Investigators – Early Career Investigator Award – Letter of Intent due September 17, 2019

Must be within 3 years of his/her last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent as of full application submission deadline.

Letter attesting to eligibility required.

  • Supports addition of new Early-Career Investigators to the unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty.
  • Early-Career Investigators whose ability to commit to conducting kidney cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
  • A Designated Mentor who is an experienced kidney cancer researcher with kidney cancer funding is required.
  • The Designated Mentor not required to be at the same institution as the Early-Career Investigator.
  • Preliminary data required.
  • Clinical trials are not allowed.
  • Maximum funding of $725,000 for direct costs (plus indirect costs).
  • Maximum period of performance years
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

 Clinical Consortia Award – Letter of Intent due September 17, 2019

Independent Investigators at or above the level of Assistant Professor (or equivalent)

  • Supports development of a consortium that will facilitate rapid execution of collaborative clinical trials that will bring to market high-impact, novel therapeutics that will ultimately and significantly decrease the impact of kidney cancer.
  • Funds may not be used for research or development of clinical protocols.
  • Trials that incorporate investigations of biomarkers for risk assessment, early detection, prediction of aggressiveness, and/or progression of prostate cancer encouraged.
  • One Coordinating Center and three clinical trial sites will be selected and be jointly responsible for proposing, selecting, and conducting trials.
  • Sites must provide plans for accruing patients from populations disproportionately affected by kidney cancer
  • Consortium expected to achieve financial self-sufficiency, such that operations can continue after the award ends.
  • The consortium is expected to achieve financial self-sufficiency, such that operations can continue after the award period ends.

Coordinating Center:

  • Maximum funding of $3M for direct costs (plus indirect costs).
  • Maximum period of performance is years
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

Clinical Trial Sites:

  • Maximum funding of $600,000 for direct costs (plus indirect costs).
  • Maximum period of performance is years
  • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the KCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

MCmoCB